Lexicon Submits Clinical Results in HCM Study, Updates ZYNQUISTA Data
Lexicon Pharmaceuticals announces completed enrollment for SONATA-HCM with Q1 2027 topline data expected; NDA resubmission for ZYNQUISTA in Type 1 diabetes nearing completion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day